Caroline Tianeze de Castro

Dr. Caroline Tianeze de Castro

Institute of Collective Health, Federal University of Bahia, Salvador, Bahia, Brazil
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
Caroline Tianeze de CastroCaroline Tianeze de Castro
Caroline Tianeze de Castro
MQMariana Jorge de Queiroz
Mariana Jorge de Queiroz
FAFlavia Caixeta Albuquerque
Flavia Caixeta Albuquerque
CBCelmário Castro Brandão
Celmário Castro Brandão
LGLeticia Farias Gerlack
Leticia Farias Gerlack
DSDjanilson Barbosa dos Santos
Djanilson Barbosa dos Santos
Background: The treatment of rheumatoid arthritis (RA), a chronic systemic inflammatory autoimmune disease, is based on disease-modifying anti-rheumatic drugs (DMARDs). Typically, it starts with conventional synthetic DMARDs (csDMARDs), and depending on the patient’s response to the treatment and the adverse events experienced, biological DMARDs (bDMARDs) are initiated. bDMARDs are more specific to inflammatory factors than csDMARDs and more efficient in inducing remission and low disease activity. Thus, this study aimed to assess the effectiveness of biological therapy in patients with rheumatoid arthritis in administrative health databases.Methods: PubMed, Embase, Lilacs, Ovid, Scopus, and Web of Science databases were searched from inception to 21 October 2021, to identify observational studies that evaluated the effectiveness of biological therapy in patients with rheumatoid arthritis using administrative databases and real-world data. The methodological quality was assessed by the methodological index for non-randomized studies (MINORS). A fixed or random-effects model estimated risk ratios with 95% confidence intervals. The analysis was divided into four groups: tumor necrosis factor inhibitors (TNFi) versus non-TNFi; TNFi versus TNFi (adalimumab, etanercept, and golimumab versus infliximab); bDMARDs versus Janus kinase inhibitors (JAKi); and bDMARDs monotherapy versus combination therapy (bDMARDs and MTX).Results: Twenty-one records were eligible for inclusion in this systematic review and meta-analysis; seven population-based cohorts, eight prospective, and six retrospective cohort studies. Overall, 182,098 rheumatoid arthritis patients were evaluated. In the meta-analysis, lower effectiveness was observed among TNFi users than in non-TNFi (RR: 0.88; 95% CI: 0.81–0.95; p < 0.01; I2 = 94.0%) and bDMARDs than in JAKi (RR: 0.86; 95% CI: 0.79–0.94; p < 0.01; I2 = 93.0%). Higher effectiveness among adalimumab, etanercept, and golimumab than in infliximab (RR: 1.19; 95% CI: 1.05–1.36; p < 0.01; I2 = 96.0%) was found. No significant differences in the effectiveness of bDMARD monotherapy compared to combination therapy (RR: 0.83; 95% CI: 0.68–1.00; p < 0.01; I2 = 81.0%) was observed. E-value analysis indicated that the estimates were not robust against unmeasured confounding.Conclusion: According to the available real-world data, our results suggest that biological therapy effectively treats patients with rheumatoid arthritis, indicating higher effectiveness with non-TNFi and JAKi than with TNFi.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID#CRD42020190838, identifier CRD42020190838.

30 December 2021 in Nutrition Reviews
Verified
Journal Article
Closed access
MLMichele S Lima
Michele S Lima
MPMarcos Pereira-Santos
Marcos Pereira-Santos
Caroline Tianeze de CastroCaroline Tianeze de Castro
Caroline Tianeze de Castro
DSDjanilson B Santos
Djanilson B Santos
Context: Epidemiological studies suggest an association between vitamin D deficiency and anemia. Evidence of this relationship in pregnant women, however, is scarce.Objective: The aim of this systematic review was to investigate the association between vitamin D deficiency and gestational anemia through observational studies.Data Sources: The PubMed, Scopus, Web of Science, ScienceDirect, Embase, and Virtual Health Library databases were searched from inception to April 2021.Study Selection: Original articles reporting observational studies that investigated the association between vitamin D deficiency and gestational anemia were included. Articles that did not have an abstract, as well as reviews articles, experimental studies, and editorials, were excluded. Two reviewers independently performed study selection, data extraction, and assessment of study quality. Disagreements between the reviewers were resolved by a third reviewer.Data Extraction: Study quality was assessed by 2 scales. Data were extracted from eligible studies and arranged in a 2 × 2 table. Odds ratios with 95% confidence intervals for the risk of the outcome were estimated using a fixed-effect model.Results: In total, 985 studies were retrieved, of which 17 were included in the systematic review: 11 cohort studies, 3 case-control studies, and 3 cross-sectional studies. For the meta-analysis, 8 studies with a total of 6530 women were included. There was a 61% increase in the odds of anemia in pregnant women with vitamin D deficiency (OR = 1.61; 95%CI, 1.41–1.83; I2 = 48%).Conclusions: Vitamin D deficiency may be a risk factor for anemia in pregnant women.Systematic Review Registration: PROSPERO registration no. CRD42020182697.

18 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Caroline Tianeze de CastroCaroline Tianeze de Castro
Caroline Tianeze de Castro
MPMarcos Pereira
Marcos Pereira
DSDjanilson Barbosa dos Santos
Djanilson Barbosa dos Santos
Background: Paracetamol is widely used to manage fever and pain during pregnancy worldwide. However, paracetamol may affect the pregnant woman and fetus, once this drug crosses the placental barrier after therapeutic doses and may impair fetal liver function, affecting fetus growth and development. Thus, this study aimed to investigate the association between paracetamol use during pregnancy and perinatal outcomes as preterm birth, low birth weight, and small for gestational age.Methods and findings: Data from 760 pregnant women within the NISAMI Cohort between June 2012 and February 2014 were analyzed. Logistic regression was used to estimate the association among paracetamol use during pregnancy and preterm birth, low birth weight, and small for gestational age. Multivariate analyses were adjusted for socioeconomic, maternal, pregnancy, and newborn covariates. Around 14% of women were exposed to paracetamol during pregnancy. A decrease in paracetamol use throughout pregnancy was observed. Lower risk of low birth weight in infants born to women exposed to the drug (OR 0.21; IC 95% 0.01–0.99) was found. Paracetamol use during pregnancy was not statistically associated with preterm birth or small for gestational age.Conclusions: The findings of this study do not suggest an increased risk of perinatal outcomes. However, it should not be assumed that paracetamol is a risk-free medication and its use must be rational.

10 January 2022 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
Caroline Tianeze de CastroCaroline Tianeze de Castro
Caroline Tianeze de Castro
RGRomana S. Gama
Romana S. Gama
MPMarcos Pereira-Santos
Marcos Pereira-Santos
MOMarcio Galvão Oliveira
Marcio Galvão Oliveira
TDTatiane Da Silva Dal-Pizzol
Tatiane Da Silva Dal-Pizzol
DSDjanilson B. Santos
Djanilson B. Santos
A high number of women are exposed to acetaminophen during pregnancy worldwide. This drug safety during pregnancy regarding preterm birth, birth weight, and fetal development has not been well desc...

30 September 2022 in Critical Reviews in Food Science and Nutrition
Verified
Journal Article
Closed access
SVSuelen Neris Almeida Viana
Suelen Neris Almeida Viana
TPTamires Do Reis Santos Pereira
Tamires Do Reis Santos Pereira
JAJanaína de Carvalho Alves
Janaína de Carvalho Alves
Caroline Tianeze de CastroCaroline Tianeze de Castro
Caroline Tianeze de Castro
LSLucas Santana C. da Silva
Lucas Santana C. da Silva
MRMariana Nougalli Roselino
Mariana Nougalli Roselino
SARS-CoV-2 is the virus that causes the new global pandemic, which has already resulted in millions of deaths, affecting the world’s health and economy. Probiotics have shown benefits in a variety of diseases, including respiratory infections, and may be beneficial in the adjunctive treatment of COVID-19. This study analyzed the effectiveness of probiotics as adjunctive treatment in reducing symptoms of patients with COVID-19, through a systematic review with meta-analysis. The EMBASE (Elsevier), Pubmed, Scopus, Web of Science and International Clinical Trials Registry Platform (ICTRP) were searched through March 16, 2022. The risk ratio (RR) with 95% confidence intervals (CIs) was estimated using a fixed-effect model. RoB 2 and ROBINS I were used to assess the risk of bias of the included studies. Nine studies were included (7 clinical trials and 2 cohorts), of which three clinical trials comprised the meta-analysis. Results showed that probiotics were associated with a significant 51% reduction in symptoms reported by COVID-19 patients (RR 0.49, 95% CI 0.40–0.61). There was a significant improvement in cough (RR 0.56, 95% CI 0.37–0.83), headaches (RR 0.17, 95% CI 0.05–0.65), and diarrhea (RR 0. 33, 95% CI 0.12–0.96) of patients on probiotic therapy. These findings suggest that probiotic supplementation is effective in improving symptoms of COVID-19.

5 December 2022 in Critical Reviews in Food Science and Nutrition
Verified
Journal Article
Closed access
DODaniela Dourado de Carvalho Oliveira
Daniela Dourado de Carvalho Oliveira
DSDanielle Cristina Guimarães da Silva
Danielle Cristina Guimarães da Silva
MKMarcio Massao Kawano
Marcio Massao Kawano
Caroline Tianeze de CastroCaroline Tianeze de Castro
Caroline Tianeze de Castro
MPMarcos Pereira-Santos
Marcos Pereira-Santos
Studies suggest an association between a gluten-free diet (GFD) and bone health in celiac disease (CD). However, the evidence on this relationship in children and adolescents is limited. Thus, this systematic review and meta-analysis aimed to analyze the effect of GFD on the bone health and anthropometric profile of children and adolescents with CD. Five databases were searched up to January, 2022 to identify relevant studies. The studies' methodological quality was evaluated using two scales. The Hedge's g standardized mean differences (SMD) with 95% confidence intervals were estimated using a random-effects model. The GRADE approach was used to assess the quality of evidence. Twenty-eight studies were included in the final review. GFD increased bone mineral content (BMC) (SMD = 0.39; 95%CI = 0.16, 0.62) and bone mineral density (BMD) (SMD = 0.29; 95%CI = 0.10, 0.47) in CD individuals. Difference in mean BMC and BMD between children and adolescents with CD versus healthy individuals was -0.49 (95%CI = -0.76, -0.22) and -0.47 (SMD = -95%CI = -0.72, -0.22), respectively. There was no difference in BMI and body fat among celiac children and adolescents versus healthy controls. In conclusion, GFD was associated with higher BMC and BMD in children and adolescents with CD.